Pharm'Up 
Global pharmaceutical leader Lupin Limited has unveiled the launch of Ipratropium Bromide Nasal Solution (Nasal Spray) in 0.03% and 0.06% concentrations across the United States. These formulations are bioequivalent to Atrovent® Nasal Spray, 0.03% and 0.06%, developed by Boehringer Ingelheim Pharmaceuticals, Inc.
The Ipratropium Bromide Nasal Solution (Nasal Spray) 0.03% is designed to provide symptomatic relief from rhinorrhea linked to allergic and nonallergic perennial rhinitis in adults and children aged 6 years and above. Meanwhile, the 0.06% version is approved for alleviating rhinorrhea associated with the common cold or seasonal allergic rhinitis in adults and children aged 5 years and older.
Ipratropium Bromide Nasal Solution (reference listed drug Atrovent®) is reported to have annual sales of approximately USD 63 million in the U.S., based on IQVIA MAT May 2025 data.
About the Author
